RESEARCH PAPER
Factors associated with progression from HIV to death in patients receiving antiretroviral therapy in Southern Iran: a 21-year survival analysis and follow-up study
1
Department of Biostatistics and Epidemiology, Faculty of Health and Nutrition, Bushehr University of Medical Sciences, Bushehr, Iran
2
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
3
HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4
Non-Communicable Diseases Research Center, Research Center for Health Sciences, Institute of Health, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran
5
Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran
Submission date: 2022-02-01
Final revision date: 2022-02-23
Acceptance date: 2022-02-23
Publication date: 2023-09-15
HIV & AIDS Review 2023;22(3):189-197
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The expansion of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) epidemic has been considered a serious issue globally, and the disease is currently a major contributing factor to morbidity and mortality rates in many developing countries. This study aimed to investigate survival rate of HIV-positive patients, and its’ contributing factors among indivi¬duals receiving antiretroviral therapy in Southern Iran.
Material and methods:
A prospective cohort study was conducted among 1,327 HIV patients, who started antiretroviral therapy (ART) between June 2000 and March 2021. Kaplan-Meier analysis and Cox proportional hazard regression analyses were applied to define the survival rate of patients.
Results:
In this study, of 1,327 registered HIV/AIDS patients who were under ART, 30.6% died during the study period. The 1-, 2-, 5-, and 10-year survival rates of the patients were 90%, 87%, 78%, and 67%, respectively. Based on the results of multivariate Cox regression analysis, older age (HR≥40/<40 = 1.48), occupation (HRunemployment/employment = 1.29), history of addiction (ORyes/no = 1.64), route of transmission (HRIDU/sexual = 0.48), baseline CD4+ < 200 (HR< 200/> 500 = 2.91), clinical stage IV (HRIV/II= 1.70), ART adherence (HRadherence/non-adherence = 0.37), time on ART > 5 (HR> 5/< 1 = 0.06), and anemia (HR yes/no = 1.58) were directly associated with the survival in patients.
Conclusions:
Mortality in adults HIV-positive patients on antiretroviral therapy is relatively high in Iran. Age, history addiction, WHO clinical stage, low CD4+ count, and anemia are associated with poor survival in HIV patients. Concerned stakeholders should focus on early detection, timely ART onset, and adherence to treatment.
The expansion of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) epidemic has been considered a serious issue globally, and the disease is currently a major contributing factor to morbidity and mortality rates in many developing countries. This study aimed to investigate survival rate of HIV-positive patients, and its’ contributing factors among indivi¬duals receiving antiretroviral therapy in Southern Iran.
Material and methods:
A prospective cohort study was conducted among 1,327 HIV patients, who started antiretroviral therapy (ART) between June 2000 and March 2021. Kaplan-Meier analysis and Cox proportional hazard regression analyses were applied to define the survival rate of patients.
Results:
In this study, of 1,327 registered HIV/AIDS patients who were under ART, 30.6% died during the study period. The 1-, 2-, 5-, and 10-year survival rates of the patients were 90%, 87%, 78%, and 67%, respectively. Based on the results of multivariate Cox regression analysis, older age (HR≥40/<40 = 1.48), occupation (HRunemployment/employment = 1.29), history of addiction (ORyes/no = 1.64), route of transmission (HRIDU/sexual = 0.48), baseline CD4+ < 200 (HR< 200/> 500 = 2.91), clinical stage IV (HRIV/II= 1.70), ART adherence (HRadherence/non-adherence = 0.37), time on ART > 5 (HR> 5/< 1 = 0.06), and anemia (HR yes/no = 1.58) were directly associated with the survival in patients.
Conclusions:
Mortality in adults HIV-positive patients on antiretroviral therapy is relatively high in Iran. Age, history addiction, WHO clinical stage, low CD4+ count, and anemia are associated with poor survival in HIV patients. Concerned stakeholders should focus on early detection, timely ART onset, and adherence to treatment.
REFERENCES (40)
1.
Teshale B, Awoke S. Survival analysis and predictors of mortality for adult HIV/AIDS patients following antiretroviral therapy in Mizan-Tepi University Teaching Hospital, Southwest Ethiopia: a retrospective cohort study. HIV AIDS Rev 2022; 21: 58-68.
2.
Hamidi O, Tapak L, Poorolajal J, Amini P. Identifying risk factors for progression to AIDS and mortality post-HIV infection using illness-death multistate model. Clin Epidemiol Global Health 2017; 5: 163-168.
4.
UNAIDS. HIV and AIDS estimates in the Islamic Republic of Iran 2020. Available from: https://www.unaids.org/en/regi....
5.
Karimi N, Safari M, Mirzaei M, Kassaeian A, Roshanaei G, Omidi T. Determining the factors affecting the survival of HIV patients: comparison of Cox model and the random survival forest method. Disease and Diagnosis 2019; 8: 124-129.
6.
Hailemariam S, Tenkolu G, Tadese H, Vata P. Determinants of survival in HIV patients: a retrospective study of Dilla University Hospital HIV cohort. Int J Virol AIDS 2016; 3: 23.
7.
Bhatta DN, Adhikari R, Karki S, Koirala AK, Wasti SP. Life expectancy and disparities in survival among HIV-infected people receiving antiretroviral therapy: an observational cohort study in Kathmandu, Nepal. BMJ Global Health 2019; 4: e001319.
8.
Gona PN, Gona CM, Ballout S, et al. Burden and changes in HIV/AIDS morbidity and mortality in Southern Africa Development Community Countries, 1990-2017. BMC Public Health 2020; 20: 1-14.
9.
Collaborators GEMRHA. Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990-2015: findings from the Global Burden of Disease 2015 study. Int J Public Health 2018; 63: 123-136.
10.
Moradi G, Piroozi B, Alinia C, et al. Incidence, mortality, and burden of HIV/AIDS and its geographical distribution in Iran during 2008-2016. Iranian J Public Health 2019; 48 (Suppl 1): 1-9.
11.
Teka Z, Mohammed K, Workneh G, Gizaw Z. Survival of HIV/AIDS patients treated under ART follow-up at the University hospital, northwest Ethiopia. Environ Health Prev Med 2021; 26: 52.
12.
Teshale AB, Tsegaye AT, Wolde HF. Incidence of mortality and its predictors among HIV positive adults on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. HIV AIDS (Auckl) 2021; 13: 31-39.
13.
Nigussie F, Alamer A, Mengistu Z, Tachbele E. Survival and predictors of mortality among adult HIV/AIDS patients initiating highly active antiretroviral therapy in Debre-Berhan Referral Hospital, Amhara, Ethiopia: a retrospective study. HIV AIDS (Auckl) 2020; 12: 757-768.
14.
Akbari M, Fararouei M, Haghdoost AA, Gouya MM, Kazerooni PA. Survival and associated factors among people living with HIV/AIDS: a 30-year national survey in Iran. J Res Med Sci 2019; 24: 5.
15.
Zolopa AR, Andersen J, Komarow L, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4: e5575.
16.
Arage G, Assefa M, Worku T, Semahegn A. Survival rate of HIV-infected children after initiation of the antiretroviral therapy and its predictors in Ethiopia: a facility-based retrospective cohort. SAGE Open Med 2019; 7: 2050312119838957.
17.
Ageru TA, Koyra MM, Gidebo KD, Abiso TL. Anemia and its associated factors among adult people living with human immunodeficiency virus at Wolaita Sodo University teaching referral hospital. PLoS One 2019; 14: e0221853.
18.
Zheng H, Wang L, Huang P, et al. Incidence and risk factors for AIDS-related mortality in HIV patients in China: a cross-sectional study. BMC Public Health 2014; 14: 1-9.
19.
Hentzien M, Dramé M, Delpierre C, et al. HIV-related excess mortality and age-related comorbidities in patients with HIV aged ≥ 60: a relative survival analysis in the French Dat’AIDS cohort. BMJ Open 2019; 9: e024841.
20.
Nishijima T, Inaba Y, Kawasaki Y, et al. Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan. AIDS (London) 2020; 34: 913-921.
21.
Mossong J, Grapsa E, Tanser F, Bärnighausen T, Newell ML. Modelling HIV incidence and survival from age-specific seroprevalence after antiretroviral treatment scale-up in rural South Africa. AIDS (London) 2013; 27: 2471-2479.
22.
Birri Makota R, Musenge E. Factors associated with HIV infection in Zimbabwe over a decade from 2005 to 2015: an interval-censoring survival analysis approach. Front Public Health 2019; 7: 262.
23.
Yaghoobi H, Ahmadinia H. Life expectancy and years of life lost in HIV patients under the care of BandarAbbas Behavioral Disorders Counseling Center. Nepal J Epidemiol 2017; 7: 702-712.
24.
Mirzaei M, Farhadian M, Poorolajal J, Kazerooni PA, Tayeri K, Mohammadi Y. Life expectancy of HIV-positive patients after diagnosis in Iran from 1986 to 2016: a retrospective cohort study at national and sub-national levels. Epidemiol Health 2018; 40: e2018053.
25.
Aung ZZ, Saw YM, Saw TN, et al. Survival rate and mortality risk factors among TB-HIV co-infected patients at an HIV-specialist hospital in Myanmar: a 12-year retrospective follow-up study. Int J Infect Dis 2019; 80: 10-15.
26.
Kyaw AT, Sawangdee Y, Hunchangsith P, Pattaravanich U. Survival rate and socio-demographic determinants of mortality in adult HIV/AIDS patients on anti-retrovial therapy (ART) in Myanmar: a registry based retrospective cohort study 2005-2015. J Health Res 2017; 31: 323-331.
27.
Manosuthi W, Charoenpong L, Santiwarangkana C. A retrospective study of survival and risk factors for mortality among people living with HIV who received antiretroviral treatment in a resource-limited setting. AIDS Res Ther 2021; 18: 71.
28.
Desai KT, Patel PB, Verma A, Bansal R. Environment and psychosocial factors are more important than clinical factors in determining quality of life of HIV-positive patients on antiretroviral therapy.Trop Doct 2020; 50: 180-186.
29.
Vinh VH, Vallo R, Giang HT, et al. A cohort study revealed high mortality among people who inject drugs in Hai Phong, Vietnam. J Clin Epidemiol 2021; 139: 38-48.
30.
Deren S, Cortes T, Dickson VV, et al. Substance use among older people living with HIV: challenges for health care providers. Front Public Health 2019; 7: 94.
31.
Petoumenos K, Law MG. Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons. Curr Opin HIV AIDS 2016; 11: 514-520.
32.
Mangal TD, Meireles MV, Pascom ARP, de Almeida Coelho R, Benzaken AS, Hallett TB. Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006-2015. BMC Infect Dis 2019; 19: 206.
33.
Weber R, Huber M, Battegay M, et al. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. HIV Med 2015; 16: 137-151.
34.
Jiang H, Xie N, Cao B, et al. Determinants of progression to AIDS and death following HIV diagnosis: a retrospective cohort study in Wuhan, China. PLoS One 2013; 8: e83078.
35.
Pehrson P, Lindbäck S, Lidman C, Gaines H, Giesecke J. Longer survival after HIV infection for injecting drug users than for homosexual men: implications for immunology. AIDS 1997; 11: 1007-1012.
36.
Biset Ayalew M. Mortality and its predictors among HIV infected patients taking antiretroviral treatment in Ethiopia: a systematic review. AIDS Res Treat 2017; 2017: 5415298.
37.
Teeraananchai S, Kerr S, Amin J, Ruxrungtham K, Law M. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med 2017; 18: 256-266.
38.
Trickey A, May MT, Vehreschild JJ, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 2017; 4: e349-e356.
39.
de Melo LSW, Lacerda HR, Campelo E, Moraes E, de Alencar Ximenes RA. Survival of AIDS patients and characteristics of those who died over eight years of highly active antiretroviral therapy, at a referral center in northeast Brazil. Braz J Infect Dis 2008; 12: 269-277.
40.
Chet LS, Ab Hamid SA, Norsa’adah Bachok, Chidambaram SK, Adnan WNAW. Survival and prognostic factors of HIV-positive patients after antiretroviral therapy initiation at a Malaysian referral hospital. Saudi J Med Med Sci 2021; 9: 135-144.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
